血清N末端B型钠尿肽前体(NT-proBNP)与肌钙蛋白I(cTnI)联合检测对慢性心力衰竭(CHF)患者诊断的临床意义

Clinical Significance of Combined Detection of Serum N-terminal B-type Natriuretic Peptide Precursor (NT-proBNP) and Troponin I (cTnI) in Patients with Chronic Heart Failure (CHF)

目的探讨血清N末端B型钠尿肽前体(NT-proBNP)与肌钙蛋白I(cTnI)联合检测对慢性心力衰竭(chronic heart failure,CHF)患者诊断的临床意义。方法选取2016年2月—2018年8月该院收治的CHF患者48例,设为治疗组,并取同期接受体检的健康者48名,设为对照组。两组均接受NT-proBNP和cTnI检测,比较两组检测结果。结果实验组NT-proBNP水平为(381.32±185.65)pg/mL,cTnI水平为(0.47±0.12)ng/mL,高于对照组的(40.88±12.36)pg/mL与(0.08±0.02)ng/mL,差异有统计学意义(t=12.677、22.210,P<0.05);实验组NYHAⅡ级患者NT-proBNP水平为(185.62±81.42)pg/mL,cTnI水平为(0.38±0.15)ng/mL,NYHAⅢ级患者NT-proBNP水平为(453.65±142.53)pg/mL,cTnI水平为(0.49±0.22)ng/mL,NYHAIV级患者NT-proBNP水平为(662.35±325.25)pg/mL,cTnI水平为(0.75±0.32)ng/mL,不同NYHA分级患者NT-proBNP具差异有统计学意义(F=15.645、20.221,P<0.05);实验组HYHAⅡ级和Ⅲ级患者cTnI水平差异无统计学意义(P>0.05);NT-proBNP联合cTnI检测诊断CHF的阳性率高于单一指标(P<0.05);不同NT-proBNP和cTnI水平CHF患者预后差异有统计学意义(P>0.05)。结论 NT-proBNP联合cTnI检测可更为有效诊断慢性心力衰竭,为临床治疗提供参考。

Objective To investigate the clinical significance of combined detection of serum N-terminal B-type natriuretic peptide precursor (NT-proBNP) and troponin I (cTnI) in patients with chronic heart failure (CHF). Methods Forty-eight patients with CHF admitted to our hospital from February 2016 to August 2018 were enrolled in the treatment group, and 48 healthy subjects who underwent physical examination at the same time were selected as the control group. Both groups received NT-proBNP and cTnI tests, and the results of the two groups were compared. Results The level of NT-proBNP in the experimental group was (381.32±185.65) pg/mL, and the level of cTnI was (0.47±0.12) ng/mL, which was higher than that of the control group (40.88±12.36) pg/mL and (0.08±0.02) ng /mL, the difference was statistically significant (t=12.677, 22.210, P<0.05);the experimental group NYHAII patients with NT-proBNP level (185.62±81.42) pg/mL, cTnI level was (0.38±0.15) ng/mL The NT-proBNP level of NYHA class III patients was (453.65±142.53) pg/mL, the level of cTnI was (0.49±0.22) ng/mL, and the level of NT-proBNP in NYHAIV patients was (662.35±325.25) pg/mL. The level of cTnI was (0.75±0.32) ng/mL, NT-proBNP was statistically significantly different in different NYHA patients (F=15.645, 20.221, P<0.05). There was no statistically significant difference in cTnI levels between the experimental group and the patients with HYHAII and III (P>0.05). The positive rate of NT-proBNP combined with cTnI in the diagnosis of CHF was higher than that of single index (P<0.05). The prognosis of patients with different NT-proBNP and cTnI levels was not statistically different(P>0.05). Conclusion NT-proBNP combined with cTnI detection can be more effective in the diagnosis of chronic heart failure, providing a reference for clinical treatment.